Literature DB >> 11588032

Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes.

T L Geiger1, P Nguyen, D Leitenberg, R A Flavell.   

Abstract

Adoptive immunotherapy using receptor-modified T lymphocytes has shown promise in preclinical studies for the treatment of infectious and malignant diseases. These modified T cells express chimeric receptors that link ligand recognition and signal transduction domains in a single gene product. Typically, a single chain Fv fragment is genetically attached to the cytoplasmic domain of the T-cell receptor (TCR) zeta chain. Modulating the signaling characteristics of chimeric receptors will be important for their application to human immunotherapy. It was hypothesized that linking coreceptor and costimulatory signaling motifs together with the zeta signaling domain will enhance receptor function. The present study compares signaling characteristics of 9 single-chain receptors consisting of the H-2K(b) extracellular and transmembrane domains and various combinations of T cell signal transduction domains. Signal transduction regions studied include the TCR zeta chain, the CD4 coreceptor, the lck protein tyrosine kinase, and the CD28 costimulatory receptor. Biochemical characteristics of the receptors, analyzed using calcium flux, receptor, and ZAP-70 phosphorylation, and lck association may be predicted from the known functions of receptor constituents. The combination of zeta together with coreceptor and costimulatory function in a single receptor maximizes chimeric receptor sensitivity and potency. Combining zeta with either the costimulatory or coreceptor function independently also enhances receptor function, though to a lesser extent. It is therefore possible to link TCR, coreceptor, and costimulatory activities in a single functional entity using modular domains. Such receptors demonstrate distinct signaling properties and should prove useful in the development of chimeric receptors for therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588032     DOI: 10.1182/blood.v98.8.2364

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Authors:  Chihaya Imai; Shotaro Iwamoto; Dario Campana
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

2.  Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.

Authors:  D H Aggen; A S Chervin; T M Schmitt; B Engels; J D Stone; S A Richman; K H Piepenbrink; B M Baker; P D Greenberg; H Schreiber; D M Kranz
Journal:  Gene Ther       Date:  2011-07-14       Impact factor: 5.250

3.  CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.

Authors:  B Altvater; S Pscherer; S Landmeier; V Niggemeier; H Juergens; J Vormoor; C Rossig
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

Review 4.  New approaches for the immunotherapy of acute myeloid leukemia.

Authors:  Terrence L Geiger; Jeffrey E Rubnitz
Journal:  Discov Med       Date:  2015-04       Impact factor: 2.970

5.  Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma.

Authors:  M Kazim Panjwani; Jenessa B Smith; Keith Schutsky; Josephine Gnanandarajah; Colleen M O'Connor; Daniel J Powell; Nicola J Mason
Journal:  Mol Ther       Date:  2016-07-12       Impact factor: 11.454

Review 6.  Ex vivo gene transfer for improved adoptive immunotherapy of cancer.

Authors:  Minhtran C Ngo; Cliona M Rooney; Jeffrey M Howard; Helen E Heslop
Journal:  Hum Mol Genet       Date:  2011-03-17       Impact factor: 6.150

7.  Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.

Authors:  Carol O'Hear; Joshua F Heiber; Ingo Schubert; Georg Fey; Terrence L Geiger
Journal:  Haematologica       Date:  2014-12-05       Impact factor: 9.941

Review 8.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

9.  Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

Authors:  Michael C Milone; Jonathan D Fish; Carmine Carpenito; Richard G Carroll; Gwendolyn K Binder; David Teachey; Minu Samanta; Mehdi Lakhal; Brian Gloss; Gwenn Danet-Desnoyers; Dario Campana; James L Riley; Stephan A Grupp; Carl H June
Journal:  Mol Ther       Date:  2009-04-21       Impact factor: 11.454

Review 10.  The promise and potential pitfalls of chimeric antigen receptors.

Authors:  Michel Sadelain; Renier Brentjens; Isabelle Rivière
Journal:  Curr Opin Immunol       Date:  2009-03-25       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.